FEATURED NEWS

FDA
October 13, 2017
FDA Approved changes to the Sustiva label, Genvoya, Norvir, Descovy and more. On October 12, 2017 the FDA approved changed to the Sustiva (efavienz) package insert to: Update information on hepatotoxicity in DOSAGE and ADMINISTRATION, WARNINGS AND PRECAUTIONS, ADVERSEREACTIONS and Patient Information sections. Update CONTRAINDICATIONS and MORE
MATEC
August 17, 2017
Adult and Adolescent Opportunistic Infections Guidlines Updated The following sections of the Guidelines for the Prevemtion and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Hepatitis B Virus infection: This section was updated to include TAF/FTC as a treatment option for patients with HBV/HIV MORE
MATEC
August 1, 2017
Adult and Adolescent Opportunistic Infections Guidelines Updated July 28, 2017: The following sections of the Guidlines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents have recently been updated: Click here to view recently updated guidlines Sections of the Pneumocystis guidlines have been MORE
FDA
June 21, 2017
FDA approves changes to the Kaletra label FDA approved changes to the Kaletra (lopinavir/ritonavir) tablet and oral solution labels. These changes include updates to the following sections: Section 2: DOSAGE and ADMINISTRATION with information about use of the oral solution with a feeding tube. 2.1 General Administration Recommendations Because MORE
MATEC
June 1, 2017
Updates to the Tuberculosis Section of the Adult and Adolescent Opportunistic Infections Guidelines May 18, 2017: The tuberculosis (TB) section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was recently updated. In this revision, the epidemiology, diagnosis, and treatment sections MORE
MATEC
May 11, 2017
FDA Updates STRIBILD and TYBOST labels May 4, 2017 The STRIBILD and TYBOST labels were updated to include revised text regarding corticosteroids as follows: STRIBILD Section 7 Drug Interaction, Table 6 was revised for systemic, inhaled, nasal, and opthalmic corticosteroids as follows. Table 6 Established and Other Potentially Significant Drug MORE
MATEC
April 7, 2017
Adult and Adolescent Opportunistic Infections Guidelines Updated U.S. Department of Health and Human Services, April 7, 2017: The Malaria section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents was recently updated. In this revision, the epidemiology and treatment sections were updated MORE
MATEC
March 24, 2017
Updates to the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents The Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV Infected Adults and Adolescents document was published in an electronic format that could be easily updated as relevant changes in prevention and MORE
MATEC
July 14, 2016
New CDC MMWR report on antibiotic-resistant gonorrhea includes concerning findings for azithromycin - one of two drugs in the only recommended treatment regimen Centers for Disease Control and Prevention (CDC), July 14, 2016. On July 14, 2016 CDC, On July 14, 2016, the Centers for Disease Control and Prevention (CDC) MMWR report titled Neisseria MORE
FDA
March 24, 2016
Update: Meningococcal Vaccine Recommendations March 18th, Chicago Department of Public Health. The Chicago Department of Public Health (CDPH) is investigating a new case of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup C reported in March 2016, 9 months following the last case tied to a Chicago-area outbreak of serogroup MORE
FDA
March 4, 2016
Updated HHS Pediatric Antiretroviral Treatment Guidelines Released >Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral, Department of Health and Human Services. Updated March 1, 2016 The HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children announces MORE
FDA
February 1, 2016
U.S. Food and Drug Administration, January 28, 2016 The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Hepatitis C is a viral disease that causes inflammation of the liver that can lead to MORE

Pages